Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma

This study has been withdrawn prior to enrollment.
(Withdrawn: study halted prematurely, prior to enrollment of first participant)
Sponsor:
Information provided by:
Burzynski Research Institute
ClinicalTrials.gov Identifier:
NCT01260103
First received: December 13, 2010
Last updated: September 16, 2013
Last verified: September 2013
  Purpose

Primary Objectives

  • To compare progression free survival (PFS), the time from randomization to progressive disease,in children with optic pathway glioma (OPG) age ≥ 6 months to < 18 years, who receive combination antineoplaston therapy (ANP therapy) vs. temozolomide (TMZ); study subjects will have 1) received prior treatment with carboplatin or cisplatin, which was terminated secondary to toxicity or progression of OPG, or 2) developed recurrence of OPG after completion of carboplatin or cisplatin therapy. PFS data will be censored on the date of the last tumor assessment documenting absence of progression for study subjects:

    • Who are alive, on study and are progression-free at the time of the analysis;
    • Who discontinue, receive no subsequent therapy and are progression-free at the time of the analysis;
    • Who are given/change therapy other than the study treatment prior to observing progression;
    • Who discontinued (due to personal preference or toxicity) with a change in therapy, withdrew, or was lost to follow-up;
    • For whom documentation of disease progression or death occurs after ≥ 2 consecutive missed tumor assessments.
  • To describe the toxicity profile for ANP therapy vs. TMZ.

Secondary Objectives:

  • To compare overall survival (OS) for subjects treated with ANP therapy vs. TMZ;
  • To compare disease stabilization rates for subjects treated with ANP therapy vs. TMZ;
  • To compare complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) rates for subjects treated with ANP therapy vs. TMZ.

Condition Intervention Phase
Optic Nerve Glioma
Drug: Temozolomide
Drug: ANP Therapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)] vs. Temozolomide in Subjects With Recurrent and / or Progressive Optic Pathway Glioma After Carboplatin or Cisplatin Therapy

Resource links provided by NLM:


Further study details as provided by Burzynski Research Institute:

Primary Outcome Measures:
  • Progression free survival (PFS) [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    PFS will be summarized using tables produced by SAS Proc Lifetest (version 9.2 or later). Standard errors will be computed using the Greenwood formula and 95% confidence intervals produced using the loglog transform. The Log Rank test will be used to compare the two treatment groups with respect to PFS. All tests will be at the two-sided 0.050 significance level.


Secondary Outcome Measures:
  • Safety Analysis [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
    Comparison of the toxicity profile for ANP therapy vs. the toxicity profile for TMZ will be accomplished using the Fisher's exact test.


Enrollment: 0
Study Start Date: December 2011
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Temozolomide (TMZ)
Study subjects receive TMZ for 13 cycles
Drug: Temozolomide
Study subjects in a fasting state receive TMZ orally once a day for five consecutive days (days 1 through 5) at a starting dose of 200 mg/m2/day. Treatment cycles are repeated every 28 days following the first daily dose of TMZ from the previous cycle. In the absence of PD or unacceptable toxicity, subjects continue to receive TMZ for a maximum of 13 cycles.
Other Names:
  • Temodar
  • TMZ
Experimental: ANP Therapy
Escalating doses of ANP therapy are given daily for 52 weeks.
Drug: ANP Therapy
Escalating doses of ANP therapy are administered for 52 weeks. If the study subject has an OR or maintains SD, ANP therapy is continued.
Other Names:
  • Antineoplastons
  • Astengenal (A10)
  • Astugenal (AS2-1)

  Eligibility

Ages Eligible for Study:   6 Months to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Children age ≥ 6 months < 18 years are eligible if they have 1) received prior treatment with carboplatin or cisplatin, which was terminated secondary to toxicity or progression of OPG or 2) developed recurrence of OPG after completion of carboplatin or cisplatin therapy.
  2. Children with or without prior RT are eligible.
  3. Histological confirmation of OPG is required unless the risks of obtaining a diagnostic biopsy are prohibitive.
  4. Evidence of OPG (≥ 5 mm), as diagnosed by MRI of the brain, with and without gadolinium contrast, within four weeks of protocol study entry is required. The MRI is interpreted by two independent neuroradiologists. If there is disagreement, a third independent neuroradiologist will adjudicate. Baseline MR spectroscopy (MRS) and positron emission tomography (PET) scan are also performed.
  5. Children who are receiving corticosteroids and, for at least one week prior to entry into the protocol study have been on the lowest dose of corticosteroids that preserves optimal neurologic function, are eligible.
  6. Children with a life expectancy of > 6 months are eligible.
  7. Children ≤ 14 years of age with a Lansky performance status of > 60 are eligible. Children > 14 years of age with a Karnofsky performance status of > 60 are eligible.
  8. Children with normal organ and marrow function (as defined below) are eligible.

    • hemoglobin ≥ 10 g/dL
    • leukocytes > 2000/mm3
    • absolute neutrophil count (ANC) >1,500/ mm3
    • serum NA+, K+, BUN within institutional normal limits
    • platelets >75,000/ mm3
    • total bilirubin < 1.5 mg/dL
    • AST(SGOT)/ALT(SGPT) <3 times institutional upper limit of normal (ULN)
    • serum creatinine < 1.5 mg/dL
  9. At the recommended therapeutic dose, the effects of ANP therapy on the developing human fetus are unknown. For this reason, women of child-bearing potential who agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to protocol study entry and for the duration of protocol study are eligible. Should a woman become pregnant or suspect she is pregnant while participating in this protocol study, she will inform her treating physician immediately.
  10. Children who are able to understand a written informed consent document, and are willing to sign it, are eligible. A subject with a parent or guardian who is able to understand a written informed consent document, and who is willing to sign it on the subject's behalf, is eligible.

Exclusion Criteria:

  1. Children receiving prior ANP or TMZ therapy are not eligible.
  2. Children with an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled hypertension (> grade 2) or psychiatric illness and/or social situations that would limit compliance with protocol study requirements are not eligible.
  3. Children with a history of congestive heart failure, deep venous thrombosis, or other cardiovascular or renal conditions that would contradict administration of high dose intravenous sodium or insertion of a subclavian venous catheter are not eligible.
  4. Pregnant women are not eligible because the teratogenic and abortifacient effects of ANP therapy in humans are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to the mother receiving ANP therapy, breastfeeding is discontinued if the mother receives ANP therapy.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01260103

Sponsors and Collaborators
Burzynski Research Institute
Investigators
Study Chair: Stanislaw R Burzynski, MD, PhD Burzynski Research Institute
  More Information

No publications provided

Responsible Party: Stanislaw R. Burzynski M.D. Ph.D., Burzynski Research Institute, Inc.
ClinicalTrials.gov Identifier: NCT01260103     History of Changes
Other Study ID Numbers: BRI-BT-54
Study First Received: December 13, 2010
Last Updated: September 16, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Burzynski Research Institute:
Optic pathway glioma, recurrent
Optic pathway glioma, progressive
Temozolomide
Temodar
TMZ
Antineoplastons
ANP therapy
Atengenal (A10)
Astugenal (AS2-1)

Additional relevant MeSH terms:
Glioma
Optic Nerve Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Astrocytoma
Optic Nerve Neoplasms
Cranial Nerve Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Peripheral Nervous System Neoplasms
Cranial Nerve Diseases
Nervous System Diseases
Optic Nerve Diseases
Eye Diseases
Temozolomide
Dacarbazine
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 23, 2014